資深專業團隊,助力高產轉化性研究

 

 

 

桐樹基因搭建了以腫瘤進化論與腫瘤基因組學標本庫為基礎的轉化性研究中心,從課題設計、研究執行(基因檢測)、數據整理及挖掘、文章撰寫、投稿修改,提供一站式轉化性研究服務。

 

深諳腫瘤克隆進化論

 

 

 

桐樹基因CTO蔡微菁以第一作者在腫瘤醫學領域頂級期刊JCO上發表論文,提出了腫瘤克隆進化與驅動基因的關系,當期JCO邀請Charles Swanton教授配發封面述評推薦此研究!

Intratumoral Heterogeneity of ALK-Rearranged and
ALK/EGFR Coaltered Lung Adenocarcinoma

2018 Impact Factor : 28.245

 

J Clin Onco. l. 2015 Nov 10;33(32):3701-9. PMID: 26416997

Intratumoral genetic heterogeneity was demonstrated to coexist with histologic heterogeneity in both single-driver and ALK/EGFR coaltered LADCs. Altered oncogenic drivers in spatially separated subclones of the same tumor may be different.

?查看文章

臨床轉化性研究碩果累累

 

 

 

各項轉化研究成果已被SCI高影響因子期刊收錄,獲國際權威雜志的廣泛認可

至今發表SCI文章影響因子總和>120分

 

ROS1 fusions in Chinese patients with non-small-cell lung cancer

2018 Impact Factor : 14.196

 

Ann Oncol. 2013 Jul;24(7):1822-7. PMID: 23514723

ROS1 fusions occurred in ∼2.0% of Chinese patients with NSCLC and had no specific clinicopathological feature. ROS1 fusion-negative patients may have a better survival than ROS1 fusion-positive patients.

?查看文章

Comprehensive Analysis of EGFRMutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations

2018 Impact Factor : 12.46

 

J Thorac Oncol. 2017 Sep;12(9):1388-1397. PMID: 28624467

The abundance of EGFR activating mutation by ARMS+ was significantly associated with objective response to EGFR-TKIs. The abundance of EGFRT790M mutation may have an adverse impact on PFS rather than ORR in advanced EGFR-mutant NSCLC patients treated with EGFR-TKIs.

?查看文章
金博棋牌官方客户端下载 甘肃11选5专家预测 江西11选五5怎么玩 贵州十一选五专家推荐号 三门峡期货配资 河北快三河北十一选五 p62中奖方式 st股票是什么意思 江西十一选五一定牛新 广东快乐十分计划qq群 河南体彩快赢481走势图